Introduction
The Eastman Kodak Company has recently described a new concept in clinical chemistry, namely the use of dry chemistry films to be used initially for colorimetric analysis [2, 3] . The glucose and urea methods were evaluated in this study following the guidelines by the National Committee for Clinical Laboratory Standards (NCCLS) [1] which are recommendations for goals to be sought by manufacturers.
This evaluation protocol is designed to provide a multipurpose evaluation framework for a wide range of methods and instruments and is in three sections. PSEP-2 (proposed standard for establishing performance claims) describes the four-week baseline period which is used to establish confidence limits for the controls used throughout the study. PSEP-3 details the precision study and PSEP-4 describes the comparison of methods experiment.
The Kodak Ektachem GLU/BUN analyser is a microprocessor controlled discrete analyser which operates in single or dual test mode. The instrument used in the present study was an engineering model used in the USA and Europe and was designed to evaluate the concept of quantitative chemical analysis using multilayered reagents. It was used according to the operators manual. The instrument was modified to give urea values, as opposed to blood urea nitrogen values, and was calibrated in mmol/L.
Methods and materials NCCLS protocol for establishing performance claims for clinical chemistry methods
The protocol is in three sections [1] . The sections and the material used are described below.
Performance check experiment PSEP-2
The protocol describes control criteria which were established for the test method. These criteria were used to control performance of the Kodak test methods during the performance of subsequent sections of the protocol. The control sera used were lyophilised human material provided by Kodak for the LOW and HIGH levels and Wellcomtrol II (Wellcome Reagents Limited, Kent, UK) for the MID-level.
Replication experiment PSEP-3 The replication (imprecision) protocol specifies a period of twenty days and a total of forty analytical runs. The 'midi' version was chosen as it is designed for medium rate automated methods. The midi experiment involves the analysis of half the number of samples compared with the maxi version, and unlike the mini experiment still enables the effects of carryover to be investigated. For each concentration level studied two different estimates of within run and total imprecision are required for presentation of performance claims. The first, designated ' [7] . With [3 ] . Cartridges containing fifty slides were stored at 4C and allowed to warm to room temperature for half an hour before the foil pack was opened. All experimental work reported here employed one coating batch, with daily calibration using three serum calibrators. Two hundred microliter samples were used for all studies.
Samples with urea values above 40 mmol/1 were diluted one in two with water.
Results
Performance check experiment (PSEP-2)
Baseline performance data for forty sets of triplicate determinations over a twenty day period appear in Table 2 , which provided performance check parameters for the replication and method comparison studies. Forty consecutive sets of readings were found using the criteria in the protocol.
Performance during the rest of the study was assessed by the mid control charts as described in the NCCLS protocol.
Charts were constructed for the high, mid and low controls. The high and low control charts were only used as corroborative evidence if an outlier occurred in the mid level charts. Throughout the study there was only one mid control outlier. One reading of a triplicate set produced a mean and range error. However, the high and low control mean and range charts were well within limits and so this run was not rejected.
Replication experiment (PSEP-3) Table 3 gives the analysis of variance (ANOVA) results for the replication experiment. It should be noted that the carryover effect on WELL-I for glucose and urea is based on testing significant differences in variance with and without carryover. Table 4 gives the claims for imprecision with and without carryover following the NCCLS format.
Comparison of methods experiment (PSEP-4)
Figures and 2 give the regression statistics together with correlation coefficient and the ratio SDx/Syx for patient samples used in the comparison of methods experiment. The preparation of data sets ez, e2 and e 3 is described in the Methods and Materials section. Regression statistics from data set e3 were used to calculate the accuracy performance claims given in Table 5 .
Wellcome Group quality control programme There were two main objectives in using the multi-level lyophilised material available from the programme:
1. To provide additional information to that obtained in the comparison of methods experiment and compare the estimates from regression analysis with those calculated from patient samples. No exclusion criteria were applied to these results as the number of samples was very small. The ratio SDx/Syx in every case was well in excess of 7.0 and no pairs showed a difference in excess of 3.5 times Syx (Table 6 Care must be taken to ensure that plasma samples are obtained from blood samples which had the recommended amounts of anticoagulant added. High concentrations of anticoagulant resulting from inadequate filling of a specimen container could adversely affect measurement by a test or comparative method [3 ] . The choice and control of the comparative method represents the second major problem in the comparison of methods experiment and whereas the protocol discusses briefly the factors affecting the choice of a comparative or reference method it does not provide guidance as to the control of that method during the period of study. The data presented in Table 6 represents an attempt to provide some information about the bias of the comparative methods with reference to their overall and method means. It can be seen that the comparative method for urea shows a significant proportional error of the order of +5% when compared against overall mean values which may account in part for the significant proportional error of approximately-5% for the Kodak results against the comparative results using patient samples.
In the preparation of accuracy performance claims it is clear that calculation of bias is dependent on reliable estimates of slope and intercept and that the tolerance limits are additionally dependent on the standard error about the regression line (Syx).
Preparation of data in the manner recommended will sometimes lead to a reduction in the range of samples analysed and additionally the removal of outliers will reduce the value of Syx. For performance claims to be comparable these factors must be taken into account. These effects are discussed in detail elsewhere [8] . The protocol suggested that tolerance limits and total error be calculated only for medical decision concentrations closest to the mean of the comparative method data (x). The estimates of slope, intercept and standard error of the estimate of y (Syx) from linear regression analysis are used in the calculation of the tolerance limits and in estimates of total error at medical decision levels, which provide a basis for manufacturers' performance claims. This paper illustrates the way in which sample number, distribution and range could alter the manufacturers' performance claims and gives an indication of the magnitude of these effects. The methods adopted for detection of outliers in the data can also have a marked effect on the claims made.
Materials and methods
Experimental methods and materials for glucose have been described previously [2] . The distribution of patient samples recommended for glucose analysis was Group A (<2.8 mmol/1) 10%; B (2.9-6.1 mmol/1) 40%; C (6.2-8.3 mmol/1) 30%; D (8.4-13.8 mmol/1) 10%; and Group E (>13.8 mmol/1) 10%. The information in the draft version of the PSEP-4 protocol contained a misprint and groups for glucose were given as A (10%), B (40%), C (20%, D (10%) and E (10%). In our experiment 20% of samples were-collected in Group E. However, the recommended distribution and our distribution have been compared with other possible distributions for one hundred samples by data modification described below.
The equations for linear regression analysis were those given in Davies et al [3] . Modification of the original data base of two hundred samples analysed in duplicate by test and comparative method is described below.
